PROJECT PREVENT: a randomized controlled trial of preoperative vaginal metronidazole to decrease patient issues and infections after hysterectomy.

Autor:	Pradhan T; Obstetrics and Gynecology, Westchester Medical Center, New York Medical College, Valhalla, New York, USA., Zhang H; Obstetrics and Gynecology, Westchester Medical Center, New York Medical College, Valhalla, New York, USA., Kadesh A; Obstetrics and Gynecology, Jefferson Abington Hospital, Abington, Pennsylvania, USA., Buskwofie A; Obstetrics and Gynecology, Westchester Medical Center, New York Medical College, Valhalla, New York, USA., Patankar S; Obstetrics and Gynecology, RWJ Barnabas Health, New Brunswick, New Jersey, USA., Menon S; Obstetrics and Gynecology, Westchester Medical Center, New York Medical College, Valhalla, New York, USA., Ryntz T; Obstetrics and Gynecology, Westchester Medical Center, New York Medical College, Valhalla, New York, USA., Grimes CL; Obstetrics and Gynecology, Westchester Medical Center, New York Medical College, Valhalla, New York, USA.; Urology, Westchester Medical Center, New York Medical College, Valhalla, New York, USA.
Jazyk:	angličtina
Zdroj:	BMJ surgery, interventions, & health technologies [BMJ Surg Interv Health Technol] 2024 Apr 04; Vol. 6 (1), pp. e000241. Date of Electronic Publication: 2024 Apr 04 (Print Publication: 2024).
DOI:	10.1136/bmjsit-2023-000241
Abstrakt:	Objectives: To evaluate if vaginal metronidazole for 5 days before hysterectomy decreases postoperative infections and patient issues. Design: This randomized trial compared vaginal metronidazole for 5 days before a scheduled hysterectomy to no intervention. Sample size calculation was based on a 20% difference in issues and infection (30% incidence and 10% in the intervention arm) with 80% power and an alpha error of 0.05 and indicated 62 subjects needed in each arm. Setting: Outpatient gynecology clinics at a single academic institution. Participants: 154 subjects were screened for eligibility between July 2020 and September 2022. 133 underwent hysterectomy including 68 subjects (51.1%) randomized to the metronidazole and 65 (48.9%) controls. Overall, the population was racially and ethnically diverse. There was no significant difference in characteristics between the two groups. Interventions: Vaginal metronidazole for 5 days before hysterectomy. Main Outcome Measures: Postoperative patient issues and documented postoperative infections at 4-8 weeks after surgery. Results: There was no difference in the composite rate of patient-reported issues and/or documented postoperative infection (53/133 (39.8%) with no difference between groups (29/68 (42.6%) vs 24/65 (36.9%), p=0.50). There was no difference in patient-reported issues which was 51/133 (38.3%) with no difference between groups (28/68 (41.2%) vs 23/65 (33.8%), p=0.49) or in documented infections with a rate of 25/133 (18.8%) with no significant difference between groups (15/68 (22.0%) vs 10/65 (15.4%), p=0.33). In the intervention arm, the compliance rate was 73.5% for all 5 days of vaginal metronidazole, and a per-protocol analysis was performed which resulted in no significant difference between groups. Conclusions: There is insufficient evidence to suggest a significant benefit of preoperative vaginal metronidazole to prevent surgical site infections and postoperative patient issues in patients undergoing hysterectomy. Trial Registration Number: ClinicalTrials.gov, NCT04478617. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu